Search
Now showing items 31-40 of 174
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
(2017-09-12)
OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS: In the 2-year Comparison of Alemtuzumab and ...
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
(2018-04)
Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective: ...
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
(Elsevier/Science Direct, 2018-11-02)
BACKGROUND: Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with ...
e-Health and multiple sclerosis: An update.
(2018-11)
e-Health (or digital healthcare) is becoming increasingly relevant in multiple sclerosis (MS) clinical management. We aim to review and discuss current status and future perspective of e-health in people with multiple ...
Alemtuzumab depletion failure can occur in multiple sclerosis.
(2018-06)
Alemtuzumab is a lymphocyte-depleting antibody and one of the most effective treatments for relapsing multiple sclerosis. However, it also causes loss of immune-tolerance leading to secondary autoimmunity and marked anti-drug ...